COL5A1 and systemic sclerosis: In this context, we contemplate that therapies targeting the Col V segments mostly involved in SSc-triggering autoimmunity, such as the α1(V) chain and the Col5A1(1049) and Col5A1(1439) synthetic peptides, could produce a more efficient response and become a potential immunotherapeutic strategy in the treatment of SSc.